To the Editor: Dr Yeni and colleagues make
the following 2 statements about underpowered trials in describing updated
recommendations of the International AIDS Society-USA Panel for the treatment
of adult HIV infection1: (1) "Nevirapine
has been studied in the ATLANTIC trial . . . . Although not powered to provide
definitive conclusions, the results suggested that activity of nevirapine
in a multidrug regimen was similar to that of indinavir." (2) "Comparability
in viral suppression at 36 weeks between nevirapine-containing and nelfinavir-containing
regimens (each with 2 nRTIs [nucleoside reverse transcriptase inhibitors)
has been reported." In our opinion, both statements are misleading. In addition
to other concerns about underpowered trials,2 such
results may also be used to support questionable therapeutic practices.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.